Tearsheet

Perspective Therapeutics (CATX)

Market Price (12/29/2025): $2.87 | Market Cap: $213.2 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Perspective Therapeutics (CATX)

Market Price (12/29/2025): $2.87
Market Cap: $213.2 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -80%	Weak multi-year price returns 2Y Excs Rtn is -60%, 3Y Excs Rtn is -77%	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -95 Mil
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -54%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -80%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
2	Weak multi-year price returns 2Y Excs Rtn is -60%, 3Y Excs Rtn is -77%
3	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
4	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -95 Mil
6	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -54%

Valuation, Metrics & Events

	12/29/25	2024	2023	2022
Share Price CYE	$2.87	$3.19	$4.02	$2.47
Market Cap CYE ($ Mil)	213.2	225.9	113.3	35.1
Total Debt ($ Mil)	3.3	4.1	2.6	0.4
Total Cash ($ Mil)	174.1	226.9	9.2	43.8
Enterprise Value ($ Mil)	42.4	230.0	115.9	35.5
Valuation Ratios
P/S TTM	-	-	-	9.9
P/EBIT TTM	-2.0	-2.6	-2.7	-4.6
P/E TTM	-2.0	-2.6	-2.3	-4.8
P/FCF TTM	-2.0	-2.8	-2.8	-5.6
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9	4.5
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5

	12/29/25	2024	2023
Share Price CYE	$2.87	$3.19	$4.02
Market Cap CYE ($ Mil)	213.2	225.9	113.3
Total Debt ($ Mil)	3.3	4.1	2.6
Total Cash ($ Mil)	174.1	226.9	9.2
Enterprise Value ($ Mil)	42.4	230.0	115.9
Valuation Ratios
P/S TTM	-	-	-
P/EBIT TTM	-2.0	-2.6	-2.7
P/E TTM	-2.0	-2.6	-2.3
P/FCF TTM	-2.0	-2.8	-2.8
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

null

AI Analysis | Feedback

Metric	Value	Date	Source
Total Patients Dosed in [212Pb]VMT-α-NET Phase 1/2a Trial	55	9122025	Link
Objective Response Rate in [212Pb]VMT-α-NET Phase 1/2a Trial (Cohort 2)	44%	9122025	Link
Number of Clinical-Stage Radiopharmaceutical Therapies	3	5122025	Link
U.S. Manufacturing Facilities	2 operational, 3 in development	5122025	Link
Patent Portfolio Extension	Through 2041-2044	5122025	Link
Clinical Trial Collaborations	Bristol Myers Squibb, Lantheus Holdings, Mayo Clinic	9152025	Link

Upcoming
3/25/2026	Earnings Release	Rev: - EPS: -

CATX Stock

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

1. Persistent Bearish Trend and Sentiment: Analysis during the period indicated a prevalent bearish outlook for Perspective Therapeutics (CATX). The asset price was noted to be in a long-term downtrend, with multiple sources, including Gov.Capital, pointing to a declining tendency since 2005. Additionally, StockInvest.us observed a "very wide and falling trend in the short term" for CATX stock, signaling further potential declines. Intellectia AI also concluded a "falling trend" and identified the stock as a "Strong Sell candidate" as of December 27, 2025.

2. Negative Price Predictions and Forecasts: Multiple financial forecasting platforms projected significant future declines for CATX, contributing to negative investor sentiment within the specified period. Walletinvestor.com, for instance, predicted a drastic drop of -99.996% for CATX stock from $2.810 to $0.0001054, labeling it a "bad, high-risk 1-year investment option." Gov.Capital forecast substantial decreases for CATX over three months (-30.22%), six months (-50.56%), and one year (-76.25%) from December 25, 2025. Similarly, StockInvest.us anticipated a fall of -30.97% over the subsequent three months from December 24, 2025.

Show more

Stock Movement Drivers

Fundamental Drivers

The -15.3% change in CATX stock from 9/28/2025 to 12/28/2025 was primarily driven by a -0.1% change in the company's Shares Outstanding (Mil).

	9282025	12282025	Change
Stock Price ($)	3.40	2.88	-15.29%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	74.23	74.30	-0.08%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

9/28/2025 to 12/28/2025

	Return	Correlation
CATX	-15.3%
Market (SPY)	4.3%	-8.3%
Sector (XLV)	15.2%	-15.5%

Fundamental Drivers

The -23.4% change in CATX stock from 6/29/2025 to 12/28/2025 was primarily driven by a -2.7% change in the company's Shares Outstanding (Mil).

	6292025	12282025	Change
Stock Price ($)	3.76	2.88	-23.40%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	72.36	74.30	-2.68%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

6/29/2025 to 12/28/2025

	Return	Correlation
CATX	-23.4%
Market (SPY)	12.6%	8.3%
Sector (XLV)	17.0%	-3.4%

Fundamental Drivers

The -9.7% change in CATX stock from 12/28/2024 to 12/28/2025 was primarily driven by a -5.2% change in the company's Shares Outstanding (Mil).

	12282024	12282025	Change
Stock Price ($)	3.19	2.88	-9.72%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	70.63	74.30	-5.19%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

12/28/2024 to 12/28/2025

	Return	Correlation
CATX	-9.7%
Market (SPY)	17.0%	31.2%
Sector (XLV)	13.8%	21.5%

Fundamental Drivers

The 15.2% change in CATX stock from 12/29/2022 to 12/28/2025 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.

	12292022	12282025	Change
Stock Price ($)	2.50	2.88	15.20%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	9.95	0.00	-100.00%
P/S Multiple	3.57	∞	∞%
Shares Outstanding (Mil)	14.21	74.30	-422.95%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

Market Drivers

12/29/2023 to 12/28/2025

	Return	Correlation
CATX	-28.4%
Market (SPY)	48.4%	22.7%
Sector (XLV)	17.8%	16.9%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
CATX Return	-28%	-14%	-36%	63%	-21%	-12%	-55%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
CATX Win Rate	50%	8%	50%	33%	50%	58%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
CATX Max Drawdown	-42%	-16%	-43%	-17%	-29%	-46%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	CATX	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-91.7%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	1104.9%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-63.5%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	174.1%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	47 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-60.9%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	156.0%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	348 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-97.1%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	3366.7%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	Not Fully Recovered days	1,480 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

Perspective Therapeutics's stock fell -91.7% during the 2022 Inflation Shock from a high on 1/20/2021. A -91.7% loss requires a 1104.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Perspective Therapeutics (CATX)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

AI Analysis | Feedback

A specialized Novartis focused on developing next-generation radiopharmaceutical cancer treatments.
The BioNTech of radiopharmaceutical cancer therapies.

AI Analysis | Feedback

[212Pb]VMT-α-NET: This is Perspective Therapeutics' lead alpha-particle therapeutic candidate for treating neuroendocrine tumors.
[212Pb]PSMA TAT: This therapeutic candidate is being developed for the treatment of metastatic castration-resistant prostate cancer.
[212Pb]GRT: This therapeutic candidate targets specific solid tumors such as melanoma and small cell lung cancer.

AI Analysis | Feedback

Perspective Therapeutics (CATX) is a clinical-stage radiopharmaceutical company focused on developing targeted alpha-particle therapies for cancer. As of its latest public filings (e.g., 2023 10-K), the company does not have any products approved for commercial sale and has not generated revenue from product sales.

Consequently, Perspective Therapeutics does not currently have major commercial customers in the traditional sense of entities purchasing its products or services. Their operations are primarily focused on research and development, including conducting clinical trials to advance their therapeutic candidates. The company's funding primarily comes from equity financing and collaborations rather than sales revenue.

AI Analysis | Feedback

NorthStar Medical Radioisotopes, LLC (private company)

AI Analysis | Feedback

Thijs Spoor Chief Executive Officer

Thijs Spoor was appointed CEO in February 2023. He previously studied as a nuclear pharmacist over 30 years ago. Under his leadership, Perspective Therapeutics focuses on innovating cancer treatments using novel radiopharmaceuticals, specifically the alpha-emitting isotope Lead-212 (212Pb).

Joel Sendek Chief Financial Officer

Joel Sendek was appointed Chief Financial Officer effective September 4, 2025. He brings over 30 years of experience in the life sciences sector, having served as CFO at four prior biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. As CFO, he has a successful track record of raising over $2.5 billion in corporate transactions. His background also includes leadership roles as a senior equity research analyst at Stifel (Head of Healthcare Equity Research), Lazard, and Oppenheimer (Head of Healthcare Life Sciences Research), where he was recognized by The Wall Street Journal as an All-Star Analyst with a #1 ranking in stock picking.

Dr. Markus Puhlmann, MD MBA Chief Medical Officer

Dr. Markus Puhlmann is the Chief Medical Officer. He is a clinical researcher with over 30 years of combined experience in healthcare and the pharmaceutical industry, holding leadership positions in oncology drug development.

Jonathan Hunt Chief Accounting Officer

Jonathan Hunt serves as the Chief Accounting Officer. He previously held the role of Chief Financial Officer before the appointment of Juan Graham, and subsequently transitioned to Chief Accounting Officer.

Amos Hedt Chief Business Strategy Officer

Amos Hedt is the Chief Business Strategy Officer. He is a skilled strategist with over 20 years of biotechnology and pharmaceutical experience, providing comprehensive expertise across all stages of drug research and development.

AI Analysis | Feedback

null

AI Analysis | Feedback

A clear emerging threat for Perspective Therapeutics (CATX) is the advanced clinical development and potential market entry of directly competing alpha-emitting radiopharmaceuticals for neuroendocrine tumors (NETs).

Specifically, **RayzeBio's RYZ101 (Ac225-DOTATATE)**, now owned by Bristol Myers Squibb (BMS), represents a significant threat. RYZ101 is an alpha-particle radiopharmaceutical targeting SSTR2, which is the same indication (NETs) and mechanism of action as CATX's lead product candidate, Pb212-VMT-α-NET. RYZ101 is currently in a Phase 3 clinical trial (ACTION-1) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Given BMS's acquisition of RayzeBio for $4.1 billion, there is substantial financial backing and commitment to commercializing RYZ101. If RYZ101 successfully completes its Phase 3 trial and gains regulatory approval, it could achieve market entry significantly earlier than CATX's Pb212-VMT-α-NET, and with the immense resources of BMS, could quickly capture market share, thereby diminishing the potential market opportunity for CATX's own lead asset.

AI Analysis | Feedback

Perspective Therapeutics (CATX) is involved in developing and commercializing radiopharmaceutical technologies for various cancer treatments. The addressable markets for their main products and pipeline candidates are substantial and predominantly global.

VMT-α-NET (Neuroendocrine Tumors - NETs): The global market for neuroendocrine tumor treatment was estimated to be between USD 2.66 billion and USD 3.56 billion in 2024. This market is projected to grow to a range of approximately USD 4.89 billion by 2034 to USD 7.87 billion by 2032. North America is a significant contributor to this market.
VMT01 (Melanoma): The global malignant melanoma treatment market was valued between USD 3.9 billion and USD 9.16 billion in 2023/2024. It is projected to reach between USD 8.9 billion and USD 21.79 billion by 2033/2034. North America holds a considerable share in the melanoma therapeutics market.
PSV4XX/PSMA Alpha-PET DoubLET (PSMA-expressing prostate cancers): The global prostate cancer therapeutics market was estimated between USD 12.9 billion and USD 17.0 billion in 2024/2025. This market is anticipated to grow to a range of USD 29.2 billion by 2035 to USD 31.99 billion by 2030. The global PSMA PET imaging and treatment market, a more specific segment relevant to PSV4XX, was valued at USD 0.91 billion in 2024 and is projected to reach USD 12.18 billion by 2033. North America is a dominant region in the prostate cancer therapeutics market.
CS-1 Cesium-131 Brachytherapy Seeds (for various cancers including prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers): The global brachytherapy market was valued between USD 0.99 billion and USD 1.33 billion in 2024, with projections to reach between USD 1.99 billion by 2034 and USD 2.22 billion by 2035. Specifically, the brachytherapy seeds market was valued at USD 137.7 million in 2024 and is predicted to reach USD 224.1 million by 2034. Prostate cancer represents a significant application segment within the brachytherapy market. North America leads the global brachytherapy market.
PSV359 (Solid Tumors targeting FAP-α): The global solid tumors market was valued between USD 170.3 billion and USD 362.21 billion in 2023/2024. It is projected to grow to a range of USD 375.4 billion by 2034 to USD 1557.42 billion by 2032. Fibroblast Activation Protein (FAP) is expressed in over 90% of malignant epithelial tumors. North America dominates the solid tumors market.

AI Analysis | Feedback

Perspective Therapeutics (CATX) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives focused on its innovative radiopharmaceutical pipeline and operational advancements.

Advancement and Commercialization of Lead Pipeline Candidates: A primary driver of future revenue growth for Perspective Therapeutics will be the successful progression and potential commercialization of its lead clinical programs. The company is actively developing VMT-α-NET for neuroendocrine tumors and VMT01 for metastatic melanoma, both of which are currently in Phase 1/2a clinical trials. Positive data from these trials and subsequent advancement through regulatory pathways toward market approval are critical for generating significant revenue.
Launch and Growth of New Products from the Pipeline: Beyond its lead programs, Perspective Therapeutics has other promising candidates in its pipeline, such as PSV359, which targets FAP-α in solid tumors, and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. The company received Investigational New Drug (IND) clearance for PSV359, with patient dosing expected to commence in mid-2025. Successful development and eventual launch of these new products will broaden the company's product portfolio and create additional revenue streams.
Expansion of Target Indications for Radiopharmaceutical Therapies: The company's strategy involves expanding the range of tumors addressed by its radiopharmaceutical products. By focusing on targeted therapies that can treat various solid tumors, Perspective Therapeutics aims to increase its market positioning and offer new treatment options to a wider patient population. This expansion into additional indications could significantly increase the potential market size for its therapies.
Strengthening of Manufacturing and Supply Chain Capabilities: To support both ongoing clinical trials and future commercial operations, Perspective Therapeutics is actively expanding its manufacturing footprint. This includes establishing new facilities and enhancing its radioisotope supply chain to ensure a robust and reliable production and distribution network for its radiopharmaceutical therapies. The company has also developed a proprietary 212Pb generator to secure key isotopes, which is vital for the commercial viability and scale-up of its products.
Leveraging the Theranostic Approach for Personalized Treatment: Perspective Therapeutics is developing complementary imaging diagnostics alongside its therapeutic agents. This "theranostic" approach allows for the personalization of treatment by enabling physicians to visualize specific tumors and then deliver targeted radiation. This integrated approach has the potential to improve treatment efficacy and minimize toxicity, which could enhance market adoption and drive revenue growth by offering a more effective and tailored treatment solution.

AI Analysis | Feedback

Share Repurchases

Perspective Therapeutics, Inc. has a share repurchase program in place.

Share Issuance

The number of shares outstanding for Perspective Therapeutics increased by 67.21% in the last year.
As of October 15th, Perspective Therapeutics had issued a total of 74,260,000 shares.
The company executed a 1:10 reverse stock split on June 17, 2024.

Capital Expenditures

In the last 12 months, capital expenditures for Perspective Therapeutics were -$50.01 million.
Projected capital expenditures are $9 million for 2025, 2026, 2027, and 2028, increasing to $10 million in 2029.

	Best Bets In Health Care Sector
What You Pay
P/E	-2.0	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	-2.0	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	�	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	�	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	�	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	�	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Perspective Therapeutics Earnings Notes
2	Day 6 of Loss Streak for Perspective Therapeutics Stock with -42% Return (vs. -9.7% YTD) [10/23/2025]	Notification

	Title
0	ARTICLES

Trade Ideas

Select ideas related to CATX. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.4%	21.4%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	18.0%	18.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.9%	3.9%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	12.2%	12.2%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for Perspective Therapeutics

Peers to compare with:

Financials

	CATX	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Perspect.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	2.88	23.26	24.49	305.09	78.16	273.40	51.32
Mkt Cap	0.2	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	0	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	-95	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	-107	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	-59	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	-84	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	-38	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	CATX	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Perspect.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	-	3.2%	13.8%	4.5%	8.9%	6.0%	6.0%
Rev Chg 3Y Avg	-	-3.9%	6.5%	2.6%	3.7%	1.8%	2.6%
Rev Chg Q	-	4.2%	14.4%	9.1%	7.5%	9.6%	9.1%
QoQ Delta Rev Chg LTM	-	1.1%	3.7%	2.1%	1.8%	2.1%	2.1%
Op Mgn LTM	-	6.6%	4.8%	17.7%	22.5%	31.9%	17.7%
Op Mgn 3Y Avg	-	7.4%	7.2%	16.4%	24.2%	30.8%	16.4%
QoQ Delta Op Mgn LTM	-	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.1%
CFO/Rev LTM	-	6.7%	8.5%	20.6%	23.8%	26.6%	20.6%
CFO/Rev 3Y Avg	-	6.8%	12.7%	21.4%	26.1%	28.4%	21.4%
FCF/Rev LTM	-	5.1%	1.8%	18.1%	22.1%	23.5%	18.1%
FCF/Rev 3Y Avg	-	5.5%	4.6%	18.6%	24.6%	25.6%	18.6%

Valuation

	CATX	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Perspect.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	0.2	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	-	0.4	1.0	4.4	5.4	10.0	4.4
P/EBIT	-2.0	6.8	19.9	25.1	22.5	31.3	21.2
P/E	-2.0	8.6	572.7	36.0	29.9	41.0	33.0
P/CFO	-2.5	5.9	11.2	21.1	22.5	37.5	16.2
Total Yield	-49.4%	14.1%	2.3%	5.0%	5.4%	2.8%	3.9%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	-148.8%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	0.0	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	-0.8	0.3	0.6	0.2	0.0	0.0	0.1

Returns

	CATX	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Perspect.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	22.6%	-3.6%	12.7%	-1.1%	1.6%	-2.0%	0.2%
3M Rtn	-15.3%	-11.9%	2.7%	7.9%	17.0%	7.1%	4.9%
6M Rtn	-23.4%	-4.0%	34.5%	6.6%	15.2%	36.3%	10.9%
12M Rtn	-9.7%	-27.0%	16.2%	40.5%	34.5%	7.5%	11.8%
3Y Rtn	15.2%	-3.7%	67.3%	141.3%	79.6%	114.1%	73.5%
1M Excs Rtn	29.1%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-1.1%
3M Excs Rtn	-19.6%	-16.2%	-1.7%	3.6%	12.7%	2.8%	0.6%
6M Excs Rtn	-35.7%	-16.3%	22.3%	-5.7%	3.0%	24.0%	-1.3%
12M Excs Rtn	-24.3%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	-4.6%
3Y Excs Rtn	-76.8%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022
Filing Date	11/10/2025	3/26/2025	3/28/2024	5/1/2023
Key Financials
Total Revenue	0	0	0	4
EBITDA	-105	-78	-39	-7
Operating Income	-95	-67	-41	-8
Net Income	-106	-79	-47	-7
EPS	-1.50	-1.23	-1.74	-0.50
Growth Rates
Total Revenue Growth	-	-	-100.0%	-67.1%
EBITDA Growth	-120.3%	-100.0%	-423.8%	-4.3%
Operating Income Growth	-64.3%	-63.2%	-439.3%	-2.7%
Net Income Growth	-65.9%	-70.5%	-534.1%	-0.9%
Margins
EBITDA Margin	-	-	-	-209.8%
Operating Income Margin	-	-	-	-213.7%
Net Income Margin	-	-	-	-206.5%
Cash & Debt
Total Cash	174	227	9	44
Total Debt	3	4	3	0
Net Debt / (Cash)	-171	-223	-7	-43
Cash Flows
Net Cash from Operations	-84	-18	-37	-6
Free Cash from Operations	-107	-73	-38	-6
Returns to Shareholders
Dividends	0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	11/10/2025	8/13/2025	5/12/2025	3/26/2025	11/12/2024	8/13/2024	5/15/2024	3/28/2024	11/14/2023	8/11/2023	5/15/2023
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	0	0
Ebitda	-25	-21	-17	-42	-14	-11	-11	-11	-9	-9	-9
Operating Income	-28	-24	-22	-21	-19	-14	-13	-12	-10	-10	-10
Net Income	-26	-21	-18	-40	-15	-12	-12	-25	-10	-11	-0
EPS	-0.35	-0.29	-0.25	-0.61	-0.21	-0.18	-0.25	-0.88	-3.70	-0.40	0.00
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	0	0	0	2	4	7
Ebitda TTM	-105	-94	-84	-78	-48	-43	-41	-39	-32	-25	-17
Operating Income TTM	-95	-85	-76	-67	-58	-49	-44	-41	-33	-26	-17
Net Income TTM	-106	-95	-85	-79	-64	-59	-58	-47	-26	-18	-8
Growth Rates Quarterly
Total Revenue Growth	-	-	-	-	-	-	-	-100.0%	-100.0%	-100.0%	-100.0%
EBITDA Growth	-74.7%	-99.1%	-51.4%	-267.9%	-54.7%	-15.2%	-24.3%	-173.4%	-355.6%	-602.4%	-484.6%
Operating Income Growth	-49.5%	-68.5%	-67.9%	-78.6%	-91.1%	-46.2%	-33.5%	-178.0%	-363.0%	-608.9%	-495.7%
Net Income Growth	-71.7%	-83.6%	-48.0%	-62.8%	-46.0%	-5.4%	-3211.1%	-506.6%	-398.4%	-724.5%	76.9%
Margins Quarterly
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-	-	-	-	-
Cash & Debt
Total Cash	174	192	212	227	268	293	181	9	18	28	36
Total Debt	3	4	4	4	4	4	3	3	3	3	2
Net Debt / (Cash)	-171	-188	-208	-223	-264	-289	-178	-7	-15	-26	-34
Cash Flows Quarterly
FCF from Operations	-16	-20	-22	-27	3	-9	14	-9	-10	-8	-10
Cash Flows TTM
FCF from Operations TTM	-84	-65	-54	-18	-1	-14	-13	-37	-30	-22	-16
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-30.2%	-27.5%	-26.7%	-26.5%	-29.1%	-25.0%	-24.0%	-21.2%	-18.4%	-19.5%	-20.5%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-25.7%	-24.5%	-23.2%	-21.7%	-22.5%	-21.3%	-20.4%	-17.3%	-15.8%	-12.9%	-9.2%

Segment Financials

Operating Income by Segment

$ Mil	2024	2023	2022	2021
Total

Assets by Segment

$ Mil	2024	2023	2022	2021
Radiopharmaceutical development segment	341	98
Total	341	98

Price Behavior

Price Behavior

Market Price	$2.88
Market Cap ($ Bil)	0.2
First Trading Date	04/19/2007
Distance from 52W High	-42.2%
	50 Days	200 Days
DMA Price	$2.59	$3.01
DMA Trend	down	down
Distance from DMA	11.1%	-4.3%
	3M	1YR
Volatility	107.9%	93.8%
Downside Capture	53.23	226.33
Upside Capture	-37.31	182.17
Correlation (SPY)	-7.2%	31.5%

CATX Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.98	-1.52	-0.70	1.00	1.46	1.36
Up Beta	2.92	0.63	1.04	2.75	1.53	1.16
Down Beta	5.07	-4.55	-4.50	-2.85	0.65	0.79
Up Capture	-9%	-194%	-61%	144%	186%	348%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	9	17	27	58	116	368
Down Capture	213%	39%	154%	215%	150%	111%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	8	20	31	62	124	363

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of CATX With Other Asset Classes (Last 1Y)
	CATX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	1.1%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.2%
Annualized Volatility	93.6%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	0.43	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		22.3%	31.7%	-10.0%	-6.2%	20.0%	16.8%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of CATX With Other Asset Classes (Last 5Y)
	CATX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-9.7%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	123.8%	14.5%	17.1%	15.5%	18.7%	18.9%	48.6%
Sharpe Ratio	0.40	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		14.8%	16.9%	0.2%	2.3%	10.3%	10.3%

Based On 10-Year Data

		Comparison of CATX With Other Asset Classes (Last 10Y)
	CATX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-12.3%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	102.8%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	0.29	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		12.1%	13.4%	-0.4%	3.0%	8.4%	5.1%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	8,541,741
Short Interest: % Change Since 11302025	19.4%
Average Daily Volume	1,705,996
Days-to-Cover Short Interest	5.01
Basic Shares Quantity	74,296,000
Short % of Basic Shares	11.5%

Returns Analyses

null

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/10/2025	0.0%	-0.5%	21.6%
8/13/2025	-4.3%	-14.1%	-15.1%
3/26/2025	1.3%	-9.7%	5.3%
11/12/2024	-6.9%	-36.5%	-67.5%
8/12/2024	5.7%	17.1%	29.4%
3/28/2024	-0.8%	18.3%	31.7%
11/14/2023	8.5%	11.3%	18.6%
8/11/2023	-1.8%	-20.7%	-22.0%
...
SUMMARY STATS
# Positive	7	6	8
# Negative	11	12	10
Median Positive	5.7%	14.2%	20.1%
Median Negative	-4.3%	-10.0%	-18.5%
Max Positive	9.6%	20.7%	69.6%
Max Negative	-27.4%	-36.5%	-67.5%

	Forward Returns
11/10/2025	0.0%	-0.5%	21.6%
8/13/2025	-4.3%	-14.1%	-15.1%
3/26/2025	1.3%	-9.7%	5.3%
11/12/2024	-6.9%	-36.5%	-67.5%
8/12/2024	5.7%	17.1%	29.4%
3/28/2024	-0.8%	18.3%	31.7%
11/14/2023	8.5%	11.3%	18.6%
8/11/2023	-1.8%	-20.7%	-22.0%
2/16/2023	0.0%	-6.7%	69.6%
9/28/2022	-27.4%	20.7%	7.5%
5/10/2022	-8.7%	1.7%	-4.2%
2/8/2022	7.0%	-0.4%	-9.0%
9/21/2021	-3.7%	-2.0%	-2.0%
5/13/2021	-1.4%	2.2%	8.7%
2/9/2021	-1.1%	-3.4%	-30.7%
9/17/2020	-18.6%	-29.9%	-26.0%
5/12/2020	9.6%	-10.3%	-13.3%
2/11/2020	-5.6%	-12.2%	-38.2%
SUMMARY STATS
# Positive	7	6	8
# Negative	11	12	10
Median Positive	5.7%	14.2%	20.1%
Median Negative	-4.3%	-10.0%	-18.5%
Max Positive	9.6%	20.7%	69.6%
Max Negative	-27.4%	-36.5%	-67.5%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11102025	10-Q 9/30/2025
6302025	8132025	10-Q 6/30/2025
3312025	5122025	10-Q 3/31/2025
12312024	3262025	10-K 12/31/2024
9302024	11122024	10-Q 9/30/2024
6302024	8132024	10-Q 6/30/2024
3312024	5152024	10-Q 3/31/2024
12312023	3282024	10-K 12/31/2023
9302023	11142023	10-Q 9/30/2023
6302023	8112023	10-Q 6/30/2023
3312023	5152023	10-Q 3/31/2023
12312022	5012023	10-KT 12/31/2022
9302022	11142022	10-Q 9/30/2022
6302022	9282022	10-K 6/30/2022
3312022	5132022	10-Q 3/31/2022
12312021	2092022	10-Q 12/31/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Perspective Therapeutics (CATX)

Market Price (12/29/2025): $2.87 | Market Cap: $213.2 MilSector: Health Care | Industry: Life Sciences Tools & Services

Perspective Therapeutics (CATX)

Market Price (12/29/2025): $2.87Market Cap: $213.2 MilSector: Health CareIndustry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

CATX Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Perspective Therapeutics (CATX)

Interactive Breakdown

Better Bets than Perspective Therapeutics (CATX)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Perspective Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/29/2025): $2.87 | Market Cap: $213.2 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (12/29/2025): $2.87
Market Cap: $213.2 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services